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Key messages
What is already known about this subject?
 ► anti-tumour necrosis factor (tnF) agents are 
widely used in the treatment of ankylosing spon-
dylitis (aS) and secukinumab is the only biolog-
ic (interleukin-17a inhibitor) other than anti-tnF 
agents currently approved for the treatment of aS. 
Secukinumab has demonstrated rapid and sus-
tained benefits in clinical and radiographic outcomes 
in aS with a favourable safety profile through 4 years 
of therapy.
What does this study add?
 ► end-of-study results from the MeaSUre 1 extension 
trial represent the longest available efficacy and 
safety data reported for secukinumab in aS, and are 
notable for demonstrating no evidence of decreasing 
efficacy and a favourable and consistent safety pro-
file up to 5 years.
How might this impact on clinical practice?
 ► the results demonstrate that secukinumab is a long-
term treatment option for patients with aS for both 
biologic-naïve subjects and for those patients who 
experience an inadequate response or intolerance to 
anti-tnF agents.
AbstrAct
Objective this study aimed to report end-of-study results 
on efficacy and safety of secukinumab 150 mg through 5 
years in patients with ankylosing spondylitis (aS; MeaSUre 
1 extension trial (nct01863732)).
Methods after the 2-year core trial, 274 patients 
receiving subcutaneous secukinumab 150 or 75 mg 
(following intravenous loading or initial placebo treatment 
to 16/24 weeks) every 4 weeks were invited to enter 
the 3-year extension study. Dose escalation from 75 to 
150 mg (approved dose) was allowed at or after week 
156 based on the judgement of the treating physician. 
assessments at week 260 (5 years) included assessment 
of Spondyloarthritis international Society (aSaS) 20/40 and 
other efficacy outcomes. Data are presented as observed. 
Safety assessment included all patients who received 
≥1 dose of study treatment.
Results Of the 274 patients who entered the extension 
study, 84% (230/274) completed 5 years of treatment. 
aSaS20/40 responses were 78.6/65.2%, Bath ankylosing 
Spondylitis Disease activity index (BaSDai) 50 response 
was 63.4% and mean (±SD) BaSDai total score 
was 2.6±1.76 with secukinumab 150 mg at 5 years. 
improvements in efficacy outcomes were sustained 
through 5 years. a total of 82 patients on secukinumab 
75 mg (56.2%) had their dose escalated to 150 mg after 
week 168; aSaS40, aSaS-Pr, aSaS 5/6 and BaSDai50 
responses were improved in patients whose dose was 
escalated from secukinumab 75 to 150 mg. Secukinumab 
was well tolerated with a safety profile consistent over the 
course of the study.
Conclusions Secukinumab 150 mg provided sustained 
efficacy across multiple domains of aS with a favourable 
and consistent safety profile through 5-year treatment. 
Over 50% of patients required dose escalation from 75 to 
150 mg and efficacy improved in these patients.
InTROduCTIOn
Ankylosing spondylitis (AS) is a chronic 
inflammatory disease characterised by 
progressive, irreversible, structural damage of 
the sacroiliac and spinal joints, formation of 
syndesmophyte and ankylosis of the vertebral 
column, disability, reduced physical function 
and quality of life (QoL).1–4 The prevalence of 
AS is reported to range from 0.1% and 1.4% 
of the population,5–7 and it is associated with 
significant morbidity and disability, and thus 
constitutes a major socioeconomic burden.8
Non-steroidal anti-inflammatory drugs are 
the first-line treatment of AS. However, treat-
ment is hindered by the lack of efficacy of 
effectively all standard disease modifying anti-
rheumatic drugs (DMARDs), including sulfas-
alazine or methotrexate.9 Tumour necrosis 
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Figure 1 Patient disposition—up to 5 years (week 260). Secukinumab 75 mg arm includes patients whose dose was 
escalated to secukinumab 150 mg starting at week 168 (n=82). AE, adverse event; Pt, patient; N, number of randomised 
patients; n, number of patients with an event.
factor (TNF) blocking agents were successfully added to 
the treatment armament of AS and subsequently demon-
strated prolonged efficacy.10 11 Nevertheless, discontinua-
tion of TNF blockers has been shown to be associated with 
rapid relapse.12 Also, a major challenge with TNF inhib-
itor therapy has been loss of efficacy over time,11 with up 
to 40% of patients reported to not respond or tolerate the 
therapy.13
In chronic conditions such as AS, clinical evaluation of 
efficacy and safety of long-term treatment is important 
for informed treatment decision-making.14 Long-term 
health-related QoL and physical function through the 
control of disease activity and inflammation, as well as 
the prevention of progressive structural damage, are the 
key objectives of treatment in patients with AS.14 15
Secukinumab, a fully human monoclonal antibody 
that directly inhibits interleukin (IL)-17A, has shown 
significant and sustained efficacy in the treatment of AS 
across phase III MEASURE studies16–20 with a low rate of 
structural radiographic progression through 4 years in 
the MEASURE 1 study.16 21 Secukinumab 150 mg is the 
only approved biological DMARD for AS other than TNF 
inhibitors.2 Here, we present long-term (5 years), end-of-
study efficacy and safety results for secukinumab from the 
MEASURE 1 trial in patients with AS, including results 
for patients whose dose was escalated from secukinumab 
75 to 150 mg during the study.
MeTHOds
study design and patients
MEASURE 1 is a phase III, double-blind, randomised, 
placebo-controlled 2-year study, with 3-year extension. 
Study design and primary results have been previously 
reported.22 Patients were initially randomised to receive 
either intravenous secukinumab 10 mg/kg at baseline, 
week 2 and week 4, followed by subcutaneous secuki-
numab 150 mg (intravenous → 150 mg) or 75 mg (intra-
venous → 75 mg) every 4 weeks thereafter. Matched 
placebo was given on the same intravenous to subcuta-
neous dosing schedule. Placebo patients were re-ran-
domised to secukinumab 150 mg subcutaneous or secuki-
numab 75 mg subcutaneous (placebo switchers) by week 
16 (non-responders) or week 24 (responders). After 
the 2-year core trial (NCT01358175), patients receiving 
secukinumab 150 or 75 mg subcutaneous were invited to 
enter a 3-year extension trial (NCT1863732). Following a 
protocol amendment, dose escalation from secukinumab 
75 to 150 mg was allowed at or after week 156 or later visits 
based on the clinical judgement of the treating physi-
cians; patients were not allowed to switch to a lower dose 
once dose escalation occurred. Patients were unblinded 
at week 156 (or after approval and implementation of 
Protocol Amendment 1, whichever occurred first) and 
continued to receive the same secukinumab treatment in 
an open-label fashion. Patients were stratified according 
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Figure 2 ASAS20/40 response rates through 5 years in secukinumab 150 group (n=87). Data shown are as observed through 
5 years in patients originally randomised to secukinumab 150 mg without placebo switchers or patients whose dose was 
escalated. ASAS, Assessment of SpondyloArthritis international Society; N, number of patients randomised; n, number of 
patients assessed.
Figure 3 ASAS20/40 response rates in anti–TNF-naïve patients in secukinumab 150 group through 5 years (n=70). Data 
shown are as observed through 5 years in patients originally randomised to secukinumab 150 mg without placebo switchers 
or patients whose dose was escalated. ASAS, Assessment of SpondyloArthritis international Society; N, number of patients 
randomised, n, number of patients assessed; TNF, tumour necrosis factor.
to previous anti-TNF therapy (patients who were naïve 
to anti-TNF therapy (anti-TNF–naïve) or those with a 
history of inadequate response or intolerance to one of 
these agents (anti-TNF–IR)).
endpoints and assessments
Efficacy assessments at week 260 (5 years) included 
Assessment of SpondyloArthritis international Society 
(ASAS) criteria 20 response; ASAS40 response; ASAS5/6 
response; Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI) score; BASDAI50 response; Bath Anky-
losing Spondylitis Functional Index (BASFI) score; Bath 
Ankylosing Spondylitis Metrology Index (BASMI) score; 
Short Form-36 Physical Component Summary (SF-36 PCS) 
score; ASAS partial remission (ASAS-PR) response; Anky-
losing Spondylitis Disease Activity Score-C-reactive Protein 
(ASDAS-CRP) inactive disease response; the Functional 
Assessment of Chronic Illness Therapy fatigue question-
naire (FACIT-Fatigue) score; overall safety and tolerability. 
Assessments in patients whose dose was escalated from 75 
to 150 mg included ASAS20, ASAS40, ASAS-PR, ASAS5/6 
and BASDAI50 (up to 72 weeks after dose escalation).
statistical analysis
Extension full analysis set (FAS) comprised of all patients 
enrolled in the extension study. Efficacy results are reported 
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Table 1 Summary of key efficacy outcomes through 5 years (week 260)
Efficacy endpoints
Secukinumab 150 mg* (n=128)
Week 52 Week 104 Week 156 Week 208 Week 260
ASAS20, n/M (%) 97/122 (79.5) 91/117 (77.8) 96/126 (76.2) 92/116 (79.3) 88/112 (78.6)
ASAS40, n/M (%) 81/122 (66.4) 70/117 (59.8) 76/126 (60.3) 69/116 (59.5) 73/112 (65.2)
ASAS partial remission, n/M (%) 34/122 (27.9) 32/117 (27.4) 31/126 (24.6) 32/116 (27.6) 39/112 (34.8)
BASDAI50, n/M (%) 68/122 (55.7) 59/117 (50.4) 69/126 (54.8) 69/117 (59.0) 71/112 (63.4)
ASDAS-CRP inactive disease, n/M 
(%)
31/122 (25.4) 32/117 (27.4) 30/124 (24.2) 29/115 (25.2) 30/110 (27.3)
ASDAS-CRP less than 2.1, n/M (%) 77/122 (63.1) 73/117 (62.4) 78/124 (62.9) 69/115 (60.0) 75/110 (68.2)
ASAS5/6, n/M (%) 81/122 (66.4) 71/117 (60.7) 81/125 (64.8) 75/117 (64.1) 73/112 (65.2)
BASDAI
  M 122 117 126 117 112
  Mean±SD 2.9±1.95 3.0±1.90 2.9±1.90 2.8±1.79 2.6±1.76
  Mean change from baseline±SD −3.2±2.12 −3.2±2.10 −3.2±2.32 −3.3±2.17 −3.5±2.08
BASFI
  M 122 117 126 117 112
  Mean±SD 2.9±2.10 2.9±2.02 2.8±2.00 2.6±1.86 2.4±1.77
  Mean change from baseline±SD −2.7±2.10 −2.7±2.20 −2.7±2.26 −2.9±2.30 −3.1±2.26
BASMI
  M 117 113 120 113 108
  Mean±SD 3.3±1.50 3.3±1.54 3.2±1.48 3.3±1.53 3.2±1.49
  Mean change from baseline±SD −0.6±0.96 −0.7±1.04 −0.7±1.04 −0.6±1.18 −0.7±1.12
SF-36 PCS
  M 127 115 125 117 112
  Mean±SD 45.1±6.92 44.4±7.81 44.8±7.61 45.7±6.60 46.3±6.99
  Mean change from baseline±SD 7.7±6.99 7.3±8.11 7.5±8.62 8.3±7.64 9.0±8.06
FACIT-Fatigue
  M 127 115 126 117 111
  Mean±SD 37.1±9.58 36.6±9.47 36.4±9.66 36.9±8.85 36.9±9.35
  Mean change from baseline±SD 10.4±10.62 9.8±10.09 9.9±11.22 10.2±11.06 10.2±11.38
*Total number of patients includes placebo switchers. Data shown are as observed through 5 years.
ASAS, Assessment of SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath 
Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index;M, number of evaluable patients; N, total 
number of randomised patients; n, number of responders; SF-36 PCS, Short Form Survey-36 Physical Component Summary.
as observed data and included all patients who had avail-
able data at baseline and at each corresponding treatment 
visit. ASAS20/40 responses are reported for patients orig-
inally randomised to secukinumab 150 mg to show the 
full 5-year efficacy, and separately for all patients who 
entered the extension study in the secukinumab 150 mg 
group (ie, including patients originally randomised to 
secukinumab 150 mg and patients originally randomised 
to placebo who switched to secukinumab 150 mg at weeks 
16 or 24 (placebo switchers)). For patients who discon-
tinued during the period from week 212 to week 260 (ie, 
current treatment period for this analysis), the end of 
treatment visit (ie, final assessment 4 weeks after last study 
treatment) was considered as week 260. The dose escala-
tion subset comprised of all patients from the extension 
FAS who received at least one dose of the escalated dose. 
Safety analyses included all patients who received ≥1 dose 
of secukinumab, and data are presented as exposure 
adjusted incidence rates (EAIRs) per 100 patient-years 
over the entire treatment period. Adverse events (AEs) 
were coded using the Medical Dictionary for Regulatory 
Activities V.21.0 preferred terms (PTs) (https://www. 
meddra. org/). Safety results are reported for Any secuki-
numab, which includes all patients who received at least 
one dose of secukinumab 75 or 150 mg in core or exten-
sion study. A patient with multiple occurrences of an AE 
was counted only once in the AE category.
Data were collected in accordance with Good Clinical 
Practice guidelines by the study investigators and were 
analysed by the sponsor. Data presented here, from the 
end of study analysis at week 260 (5 years), and were 
collected up to 16 March 2018 (last patient last visit).
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Figure 4 Efficacy responses in 82 patients whose dose was escalated from secukinumab 75 to 150 mg. Pre-escalation is 
defined as the last assessment done on or before the patient took the escalated dose. Postescalation results include patients 
who had reached each respective time period at the time of the analysis. ASAS, Assessment of SpondyloArthritis international 
Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PR, partial remission.
ResulTs
Patients
Of the 371 patients who enrolled in the core study, 62% 
(230/371) completed 5 years of treatment. Of the 274 
patients who entered the extension study, 84% (230/274) 
completed 5 years of treatment. Of the 128 patients in 
the secukinumab 150 mg group (ie, including placebo 
switchers), 108 patients (84%) completed 5 years of treat-
ment (figure 1). Demographic and baseline characteristics 
have been reported previously.16 21 Approximately 80% of 
patients who entered the extension study were anti-TNF–
naïve and 83.5% (86/103) of these patients completed 5 
years of treatment.
efficacy
ASAS20 and ASAS40 responses were sustained through 
5 years in patients who were originally randomised to 
secukinumab 150 mg and were 77.6% and 64.5%, respec-
tively (figure 2). ASAS20 and ASAS40 responses with 
secukinumab 150 mg were also sustained through 5 years 
in the anti-TNF–naïve and anti-TNF–IR groups (figure 3).
In the overall group of patients that received secuk-
inumab 150 mg (ie, including placebo switchers), 
ASAS20/40 responses at 5 years were 78.6/65.2%, with 
improvements sustained across all individual ASAS 
components (online supplementary table S1). Results for 
all other efficacy endpoints were also sustained through 5 
years as shown in table 1.
efficacy following dose escalation
A total of 82 patients (56.2%) had their dose escalated 
from secukinumab 75 to 150 mg during the study, with 
the first patient having dose escalation beginning from 
week 168. ASAS20, ASAS40, ASAS-PR, ASAS 5/6 and 
BASDAI50 responses were improved in patients whose 
dose was escalated from secukinumab 75 to 150 mg 
(figure 4).
safety
The mean (±SD) exposure of Any secukinumab dose was 
1446.1 (±631.2) days. The most common AEs (incidence 
rate >5 per 100 patient-years or relative frequency >2%) 
reported with Any secukinumab dose were nasopharyn-
gitis, headache, diarrhoea and upper respiratory tract 
infection (URTI). The EAIRs of the most common AEs 
and selected AEs of interest are reported in table 2.
The infections were mainly nasopharyngitis and URTI. 
Candida infections (high-level term) were reported in a 
total of five patients in the secukinumab groups (three 
patients with oral candidiasis, one patient with Candida 
infection (PT) and one patient with genital candidi-
asis). Two opportunistic infections were reported in 
the Any secukinumab 75 mg group: herpes zoster cuta-
neous disseminated and tuberculosis (TB). The event 
of TB occurred ~2 months after the last dose of study 
treatment in a male patient with no medical history of 
TB and negative QuantiFERON TB test at screening. All 
the events of nasopharyngitis, URTI, Candida infections 
and opportunistic infections were of mild or moderate 
severity, non-serious and did not lead to study treatment 
discontinuation.
Over the 5-year treatment, nine patients were 
reported with inflammatory bowel disease (IBD) on Any 
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Table 2 Summary of secukinumab safety at 5 years (week 
260)
Variable Any secukinumab (n=360)*
Exposure (days), mean (1) 1446.1 (631.2)
Death, n (%)† 3 (0.8)
Discontinuation due to AE, n (%) 36 (10.0)
  EAIR per 100 patient-years
Any AEs, n (EAIR/100 patient-years) 319 (108.4)
Any SAEs, n (EAIR/100 patient-years) 66 (5.3)
Most common AEs, n (EAIR/100 patient-years)
  Nasopharyngitis 102 (9.3)
  Headache 54 (4.3)
  Diarrhoea 53 (4.3)
  URTI 49 (3.9)
Selected AEs of interest, n (EAIR/100 patient-years)
  Serious infections‡ 14 (1.0)
  Crohn’s disease§ 7 (0.5)
  Candida infections¶ 5 (0.4)
  Colitis ulcerative§ 2 (0.1)
  MACE§ 9 (0.6)
  Malignancies** 8 (0.6)
  Uveitis§ 24 (1.8)
Data for death and discontinuation due to AEs were not adjusted 
for exposure. Any secukinumab column includes patients that 
experienced AEs at least once on either treatments. A patient with 
multiple occurrences of an AE under one treatment was counted 
only once for the same AE for that treatment and exposure time 
is censored at the time of first event. Patients who escalated were 
counted in either treatment groups, depending on the timing of the 
AE.
*Includes all patients who were administered with at least one dose of 
secukinumab during the entire treatment period.
†One death occurred due to acute respiratory failure during core 
period; two deaths occurred during the extension period due to 
cardiac failure and stroke.
‡Rates are for events by primary system organ class (infections and 
infestations).
§Rates are for events by preferred term.
¶Rates are for events by high-level term.
**Rates are for events by standardised MedDRA query (narrow 
search).
AE, adverse event; EAIR, exposure adjusted incidence rate per 100 
patient-years; MACE, major adverse cardiac event; n, number of 
patients with an event; N, total number of patients in the safety set; 
SAE, serious adverse event; URTI, upper respiratory tract infection.
secukinumab dose (seven patients with Crohn’s disease 
(PT; EAIR of 0.6 per 100 patient-years) and two patients 
with ulcerative colitis (PT; EAIR of 0.1 per 100 patient-
years)), of which three patients had medical history of 
IBD and six patients reported de novo cases. For four 
patients (three patients with Crohn’s disease and one 
patient with ulcerative colitis), the IBD AE led to treat-
ment discontinuation. Five of the seven cases of Crohn’s 
disease were reported during the 2-year core study; two 
further cases of Crohn’s disease and the two cases of 
ulcerative colitis were reported during the 3-year exten-
sion period.
Uveitis was reported in 24 patients (EAIR of 1.8 per 
100 patient-years) across the two secukinumab treatment 
groups over the entire treatment period, of which 15 
patients had a pre-existing history and 9 were de novo. 
One event in a patient receiving secukinumab 150 mg led 
to treatment discontinuation. Twelve of the 24 cases were 
reported during the core study and 12 during the 3-year 
extension period.
Treatment-emergent anti-drug antibodies (ADAs) 
were detected in one patient in the secukinumab 150 mg 
group during the extension study. ADAs were not associ-
ated with abnormal pharmacokinetic profiles or clinically 
relevant AEs.
Four deaths occurred during the 5-year treatment 
period (two during the core study: acute respiratory 
failure, suicide and two during the extension study: cere-
brovascular accident, cardiac failure), neither of which 
was considered by the investigator to be related to study 
treatment.
dIsCussIOn
These results demonstrate that secukinumab 150 mg 
provided sustained efficacy and a favourable and 
consistent safety profile through 5 years of treatment in 
patients with AS, further building on previous evidence 
of sustained efficacy and low radiographic progression 
with secukinumab through 4 years.21
Clinical improvements were sustained across all 
endpoints through 5 years. More than half of the patients 
(82/146, 56.2%) originally randomised to secukinumab 
75 mg required dose escalation to secukinumab 150 mg 
during the study based on the clinical judgement of the 
treating physicians, highlighting that the 75 mg dose was 
suboptimal for many patients.
These results represent the longest term results 
reported for an IL-17 inhibitor in AS and are notable for 
demonstrating sustained efficacy over 5 years. Over 80% 
of patients who entered the extension study completed 
5 years of treatment, which is indicative of the sustained 
clinical benefit with long-term secukinumab therapy.
Clinical improvements with secukinumab were 
sustained in both anti-TNF–naïve and anti-TNF–IR 
subgroups. These results are consistent with the results of 
previous studies16–22 and provide additional supporting 
evidence for the use of secukinumab as a long-term treat-
ment option for both biologic-naïve patients and those 
who experience an inadequate response or intolerance 
to anti-TNF agents.
In this cohort of secukinumab-treated patients with 
active AS, the exposure adjusted incidence rates of uveitis 
and IBD (new-onset cases and flares) were 1.8 and 0.5 
per 100 patient-years, respectively, over 5 years of treat-
ment with no increase over time. Secukinumab was well 
tolerated through 5 years with a safety profile consistent 
with previous reports through 5 years16–1821 22 and a recent 
pooled analysis of long-term data in patients with psori-
asis, psoriatic arthritis and AS.23
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COnClusIOns
Secukinumab provided sustained efficacy across multiple 
domains of AS, including signs and symptoms, physical 
function and objective markers of inflammation through 
5 years. Efficacy improved in patients whose secuki-
numab dose was escalated from 75 to 150 mg (approved 
dose). The safety profile was consistent through 5 years 
of secukinumab treatment with no new or unexpected 
safety risks identified.
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